Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin
14 févr. 2023 07h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Spexis reports solid safety and pharmacokinetics results from first-in-human study with inhaled murepavadin, a novel macrocycle compound
09 janv. 2023 01h20 HE
|
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR Inhaled murepavadin shown to be well tolerated at all dose levels Program derived from Spexis’ macrocycle platformData support moving forward...
Crypto Health Market Research Report - Global Forecast to 2027 - Cumulative Impact of COVID-19
20 déc. 2022 04h03 HE
|
Research and Markets
Dublin, Dec. 20, 2022 (GLOBE NEWSWIRE) -- The "Crypto Health Market Research Report by Function, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ...
Mendus AB: Mendus presenterar positiva överlevnadsdata från ADVANCE II-studien, som utvärderar DCP-001 som underhållsbehandling vid AML, på American Society of Hematology (ASH)
12 déc. 2022 13h00 HE
|
Mendus AB
TISDAGEN DEN 13 DECEMBER 2022, KLOCKAN 8.00AM ET/2.00PM CET, GENOMFÖR MENDUS ETT WEBBSÄNT MÖTE, DÄR RESULTATEN SOM PRESENTERATS PÅ ASH KOMMER ATT DISKUTERAS Mendus AB (“Mendus” publ; IMMU.ST),...
Mendus AB: Mendus presents positive survival data from the ADVANCE II trial evaluating DCP-001 as a maintenance therapy in AML at the American Society of Hematology (ASH) meeting
12 déc. 2022 13h00 HE
|
Mendus AB
MENDUS TO HOST A WEBCAST TO DISCUSS THE ASH DATA ON TUESDAY, DECEMBER 13, 2022 AT 8.00AM ET/2.00PM CET Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies...
Healthcare Data Leader H1 Releases Its Top Predictions for 2023
07 déc. 2022 09h00 HE
|
H1
NEW YORK, Dec. 07, 2022 (GLOBE NEWSWIRE) -- H1, the connecting force for global healthcare provider, clinical, science, and research information, today released its predictions for 2023 to help life...
BioSig’s PURE EP™ System Highlighted in the Journal of Atrial Fibrillation & Electrophysiology
06 déc. 2022 08h30 HE
|
BioSig Technologies, Inc.
Westport, CT, Dec. 06, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented...
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis
11 oct. 2022 07h00 HE
|
NMD Pharma
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis Data provides first clinical proof of the mechanism of action of NMD Pharma’s...
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis
11 oct. 2022 01h00 HE
|
NMD Pharma
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis Data provides first clinical proof of the mechanism of action of NMD Pharma’s...
Nuwellis Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality at the 2022 HFSA Meeting
03 oct. 2022 07h00 HE
|
Nuwellis, Inc.
MINNEAPOLIS, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the results...